Amgen Historical Cash Flow
| AMGN Stock | USD 263.13 0.25 0.09% |
Analysis of Amgen cash flow over time is an excellent tool to project Amgen Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 3.5 B or Free Cash Flow of 4.5 B as it is a great indicator of Amgen ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Amgen Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amgen Inc is a good buy for the upcoming year.
Amgen |
About Amgen Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Amgen balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Amgen's non-liquid assets can be easily converted into cash.
Amgen Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Amgen Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Amgen operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Amgen's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. Amgen reported last year Sale Purchase Of Stock of (6.36 Billion). As of the 23rd of December 2024, Change To Liabilities is likely to grow to about 305.4 M, while Free Cash Flow is likely to drop about 4.5 B.
Amgen cash flow statement Correlations
Click cells to compare fundamentals
Amgen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amgen cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (66M) | (215M) | (165M) | (742M) | 491M | 515.6M | |
| Change In Cash | (908M) | 229M | 1.7B | (360M) | 3.3B | 3.5B | |
| Free Cash Flow | 8.5B | 9.9B | 8.4B | 8.8B | 7.4B | 4.5B | |
| Change In Working Capital | (731M) | (216M) | (1.2B) | (733M) | (484M) | (459.8M) | |
| Begin Period Cash Flow | 6.9B | 6.0B | 6.3B | 8.0B | 7.6B | 8.0B | |
| Other Cashflows From Financing Activities | (42M) | (90M) | (78M) | 6.5B | (72M) | (68.4M) | |
| Depreciation | 2.2B | 3.6B | 3.4B | 3.4B | 4.1B | 4.3B | |
| Other Non Cash Items | (186M) | (195M) | 1.3B | 1.3B | (991M) | (941.5M) | |
| Capital Expenditures | 618M | 608M | 880M | 936M | 1.1B | 663.6M | |
| Total Cash From Operating Activities | 9.2B | 10.5B | 9.3B | 9.7B | 8.5B | 5.1B | |
| Net Income | 7.8B | 7.3B | 5.9B | 6.6B | 6.7B | 3.4B | |
| Total Cash From Financing Activities | (15.8B) | (4.9B) | (8.3B) | (4.0B) | 21.0B | 22.1B | |
| End Period Cash Flow | 6.0B | 6.3B | 8.0B | 7.6B | 10.9B | 11.5B | |
| Sale Purchase Of Stock | (17.8B) | (7.7B) | (3.5B) | (5.0B) | (6.4B) | 0.0 | |
| Change To Account Receivables | (504M) | (427M) | (429M) | (746M) | (1.0B) | (964.3M) | |
| Change To Liabilities | (25M) | 779M | (567M) | 268M | 241.2M | 305.4M | |
| Other Cashflows From Investing Activities | (13.7B) | (75M) | 1.6B | (3.7B) | 225M | 236.3M | |
| Change To Netincome | 205M | (152M) | 3.4B | 485M | 557.8M | 379.4M | |
| Investments | 20.0B | (4.7B) | 733M | (6.0B) | (2.6B) | (2.5B) | |
| Change Receivables | (504M) | (427M) | (429M) | (746M) | (671.4M) | (637.8M) | |
| Net Borrowings | (4.5B) | 2.5B | 795M | 6.6B | 6.0B | 6.3B | |
| Total Cashflows From Investing Activities | 5.7B | (5.4B) | 733M | (6.0B) | (26.2B) | (24.9B) | |
| Dividends Paid | 3.5B | 3.8B | 4.0B | 4.2B | 4.6B | 2.9B | |
| Cash And Cash Equivalents Changes | (908M) | 229M | 1.7B | (360M) | (324M) | (307.8M) | |
| Cash Flows Other Operating | (136M) | (353M) | 1.5B | 487M | 560.1M | 689.6M | |
| Change To Operating Activities | 406M | 1.1B | 119M | 1.0B | 1.2B | 637.1M |
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
Moving against Amgen Stock
| 0.84 | VCYT | Veracyte | PairCorr |
| 0.83 | DRTS | Alpha Tau Medical | PairCorr |
| 0.82 | VCEL | Vericel Corp Ord | PairCorr |
| 0.73 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
| 0.66 | CDIOW | Cardio Diagnostics | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.82 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.